1 Min Read
Sept 5 (Reuters) - Anthem Inc
* Anthem has issued a positive coverage decision for Nanostring’s Prosigna breast cancer gene signature assay Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.